Cargando…

The Uro-oncology Patient and Vaccination Against SARS-CoV-2

As of April 13, 2021, 137 million cases of COVID-19 and 2.95 million deaths have been reported worldwide. On December 21, 2020, the Pfizer-BioNTech vaccine was approved for use in the European Union, with efficacy of 95% protection against COVID-19 infection. Several other vaccines are at different...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez Socarrás, Moises, Gómez Rivas, Juan, Teoh, Jeremy Yuen-Chun, Puente, Javier, Moschini, Marco, Moreno-Sierra, Jesús
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156907/
https://www.ncbi.nlm.nih.gov/pubmed/34075362
http://dx.doi.org/10.1016/j.euros.2021.05.007
_version_ 1783699559505985536
author Rodriguez Socarrás, Moises
Gómez Rivas, Juan
Teoh, Jeremy Yuen-Chun
Puente, Javier
Moschini, Marco
Moreno-Sierra, Jesús
author_facet Rodriguez Socarrás, Moises
Gómez Rivas, Juan
Teoh, Jeremy Yuen-Chun
Puente, Javier
Moschini, Marco
Moreno-Sierra, Jesús
author_sort Rodriguez Socarrás, Moises
collection PubMed
description As of April 13, 2021, 137 million cases of COVID-19 and 2.95 million deaths have been reported worldwide. On December 21, 2020, the Pfizer-BioNTech vaccine was approved for use in the European Union, with efficacy of 95% protection against COVID-19 infection. Several other vaccines are at different stages of assessment by the European Medicines Agency. In addition to the elderly, oncology patients are a vulnerable population in which COVID-19 infection may be more severe. However, owing to the design of the initial studies, evidence on the safety and efficacy of vaccination against SARS-CoV-2 in these patients is scarce and recommendations are based on the opinion of associations, stakeholders, and experts via extrapolation of information and experience for other vaccines, especially influenza vaccines. Despite the limited evidence, the consensus is that SARS-CoV-2 vaccines are safe and vaccination of oncology patients and their close relatives is recommended, although efficacy may be lower in patients with an impaired immune response and the need for additional booster doses is not yet clear. Recommendations include avoiding the use of vaccines based on viral vectors for patients with an impaired immune response, deferring vaccination for immunosuppressed patients or administering the vaccine before immunosuppression, and avoiding chemotherapy receipt between the two doses of a vaccine or on the same day that the vaccine is administered. These recommendations can be extrapolated to urology patients and although evidence is lacking, there should not be greater interference with SARS-CoV-2 vaccines from androgen deprivation therapy or intravesical bacillus Calmette-Guérin. However, large studies to provide strong evidence for uro-oncology patients are needed. PATIENT SUMMARY: We looked at the effects of COVID-19 vaccination for patients with urological cancers. The consensus is that the vaccines are safe, and vaccination of cancer patients and their close relatives is recommended.
format Online
Article
Text
id pubmed-8156907
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81569072021-05-28 The Uro-oncology Patient and Vaccination Against SARS-CoV-2 Rodriguez Socarrás, Moises Gómez Rivas, Juan Teoh, Jeremy Yuen-Chun Puente, Javier Moschini, Marco Moreno-Sierra, Jesús Eur Urol Open Sci Brief Correspondence As of April 13, 2021, 137 million cases of COVID-19 and 2.95 million deaths have been reported worldwide. On December 21, 2020, the Pfizer-BioNTech vaccine was approved for use in the European Union, with efficacy of 95% protection against COVID-19 infection. Several other vaccines are at different stages of assessment by the European Medicines Agency. In addition to the elderly, oncology patients are a vulnerable population in which COVID-19 infection may be more severe. However, owing to the design of the initial studies, evidence on the safety and efficacy of vaccination against SARS-CoV-2 in these patients is scarce and recommendations are based on the opinion of associations, stakeholders, and experts via extrapolation of information and experience for other vaccines, especially influenza vaccines. Despite the limited evidence, the consensus is that SARS-CoV-2 vaccines are safe and vaccination of oncology patients and their close relatives is recommended, although efficacy may be lower in patients with an impaired immune response and the need for additional booster doses is not yet clear. Recommendations include avoiding the use of vaccines based on viral vectors for patients with an impaired immune response, deferring vaccination for immunosuppressed patients or administering the vaccine before immunosuppression, and avoiding chemotherapy receipt between the two doses of a vaccine or on the same day that the vaccine is administered. These recommendations can be extrapolated to urology patients and although evidence is lacking, there should not be greater interference with SARS-CoV-2 vaccines from androgen deprivation therapy or intravesical bacillus Calmette-Guérin. However, large studies to provide strong evidence for uro-oncology patients are needed. PATIENT SUMMARY: We looked at the effects of COVID-19 vaccination for patients with urological cancers. The consensus is that the vaccines are safe, and vaccination of cancer patients and their close relatives is recommended. Elsevier 2021-05-27 /pmc/articles/PMC8156907/ /pubmed/34075362 http://dx.doi.org/10.1016/j.euros.2021.05.007 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Brief Correspondence
Rodriguez Socarrás, Moises
Gómez Rivas, Juan
Teoh, Jeremy Yuen-Chun
Puente, Javier
Moschini, Marco
Moreno-Sierra, Jesús
The Uro-oncology Patient and Vaccination Against SARS-CoV-2
title The Uro-oncology Patient and Vaccination Against SARS-CoV-2
title_full The Uro-oncology Patient and Vaccination Against SARS-CoV-2
title_fullStr The Uro-oncology Patient and Vaccination Against SARS-CoV-2
title_full_unstemmed The Uro-oncology Patient and Vaccination Against SARS-CoV-2
title_short The Uro-oncology Patient and Vaccination Against SARS-CoV-2
title_sort uro-oncology patient and vaccination against sars-cov-2
topic Brief Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156907/
https://www.ncbi.nlm.nih.gov/pubmed/34075362
http://dx.doi.org/10.1016/j.euros.2021.05.007
work_keys_str_mv AT rodriguezsocarrasmoises theurooncologypatientandvaccinationagainstsarscov2
AT gomezrivasjuan theurooncologypatientandvaccinationagainstsarscov2
AT teohjeremyyuenchun theurooncologypatientandvaccinationagainstsarscov2
AT puentejavier theurooncologypatientandvaccinationagainstsarscov2
AT moschinimarco theurooncologypatientandvaccinationagainstsarscov2
AT morenosierrajesus theurooncologypatientandvaccinationagainstsarscov2
AT rodriguezsocarrasmoises urooncologypatientandvaccinationagainstsarscov2
AT gomezrivasjuan urooncologypatientandvaccinationagainstsarscov2
AT teohjeremyyuenchun urooncologypatientandvaccinationagainstsarscov2
AT puentejavier urooncologypatientandvaccinationagainstsarscov2
AT moschinimarco urooncologypatientandvaccinationagainstsarscov2
AT morenosierrajesus urooncologypatientandvaccinationagainstsarscov2